These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 8971983)

  • 1. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments.
    Schwarting RK; Huston JP
    Prog Neurobiol; 1996 Oct; 50(2-3):275-331. PubMed ID: 8971983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae.
    Schwarting RK; Huston JP
    Prog Neurobiol; 1996 Jun; 49(3):215-66. PubMed ID: 8878304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
    Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
    Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF; Leo G; Vergoni AV; Martínez E; Hockemeyer J; Lluis C; Franco R; Fuxe K; Ferré S
    Brain Res Bull; 2004 Aug; 64(2):155-64. PubMed ID: 15342103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
    Fleming SM; Delville Y; Schallert T
    Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease.
    Prinz A; Selesnew LM; Liss B; Roeper J; Carlsson T
    Exp Neurol; 2013 Oct; 248():236-45. PubMed ID: 23810738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral and neurochemical dynamics of neurotoxic meso-striatal dopamine lesions.
    Schwarting RK; Huston JP
    Neurotoxicology; 1997; 18(3):689-708. PubMed ID: 9339817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurochemical responses to 6-hydroxydopamine and L-dopa therapy: implications for Parkinson's disease.
    Zigmond MJ; Hastings TG; Abercrombie ED
    Ann N Y Acad Sci; 1992 May; 648():71-86. PubMed ID: 1637074
    [No Abstract]   [Full Text] [Related]  

  • 11. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants.
    Winkler C; Bentlage C; Nikkhah G; Samii M; Björklund A
    Exp Neurol; 1999 Feb; 155(2):165-86. PubMed ID: 10072293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine neurons grafted unilaterally to the nucleus accumbens affect drug-induced circling and locomotion.
    Brundin P; Strecker RE; Londos E; Björklund A
    Exp Brain Res; 1987; 69(1):183-94. PubMed ID: 3125059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compromised circadian function in Parkinson's disease: enucleation augments disease severity in the unilateral model.
    Willis GL; Kelly AM; Kennedy GA
    Behav Brain Res; 2008 Nov; 193(1):37-47. PubMed ID: 18547659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.
    Jeon MY; Lee WY; Kang HY; Chung EJ
    Neurol Res; 2007 Apr; 29(3):289-95. PubMed ID: 17509229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
    Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts.
    Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK
    Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurokinin B/NK3 receptors exert feedback inhibition on L-DOPA actions in the 6-OHDA lesion rat model of Parkinson's disease.
    Zhang X; Andren PE; Chergui K; Svenningsson P
    Neuropharmacology; 2008 Jun; 54(7):1143-52. PubMed ID: 18423776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice.
    Iancu R; Mohapel P; Brundin P; Paul G
    Behav Brain Res; 2005 Jul; 162(1):1-10. PubMed ID: 15922062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson's disease.
    Nichols NF; Cimini MG; Haas JV; Staton BA; Tedroff J; Svensson KA
    Neuropharmacology; 2002 Oct; 43(5):817-24. PubMed ID: 12384167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.